» Articles » PMID: 24293105

Carcinoembryonic Antigen Expression Level As a Predictive Factor for Response to 5-fluorouracil in Colorectal Cancer

Overview
Journal Mol Biol Rep
Specialty Molecular Biology
Date 2013 Dec 3
PMID 24293105
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Carcinoembryonic antigen (CEA) expression has been shown to protect cancer cell lines from apoptosis and anoikis. The aim of this study was to further elucidate the role of CEA expression on resistance to anticancer drugs in human colorectal cancer (CRC). We transfected CEA negative CRC cell line SW742 as well as CHO cells to overexpress CEA and their chemoresistance were assessed by MTT assay. In comparison to the parental cell lines, transfected cells had significantly increased resistance to 5-fluorouracil (5-FU). The results also showed a direct correlation between the amount of cellular CEA protein and 5-FU resistance in CEA expressing cells. We found no significant difference in sensitivity to cisplatin and methotrexate between CEA-transfected cells and their counter parental cells. We also compared the association between CEA expression and chemoresistance of 4 CRC cell lines which differed in the levels of CEA production. The CEA expression levels in monolayer cultures of these cell lines did not correlate with the 5-FU resistance. However, 5-FU treatment resulted in the selection of sub-populations of resistant cells that displayed increased CEA expression levels by increasing drug concentration. We analyzed the effect of 5-FU in a 3D multicellular culture generated from the two CRC cell lines, LS180 and HT29/219. Compared with monolayer culture, CEA production and 5-FU resistance in both cell lines were stimulated by 3D growth. In comparison to the 3D spheroids of parental CHO, we observed a significantly elevated 5-FU resistance in 3D culture of the CEA-expressing CHO transfectants. Our findings suggest that the CEA level may be a suitable biomarker for predicting tumor response to 5-FU-based chemotherapy in CRC.

Citing Articles

Design and development of dual targeting CAR protein for the development of CAR T-cell therapy against KRAS mutated pancreatic ductal adenocarcinoma using computational approaches.

Ramalingam P, Premkumar T, Sundararajan V, Hussain M, Arumugam S Discov Oncol. 2024; 15(1):592.

PMID: 39453574 PMC: 11511808. DOI: 10.1007/s12672-024-01455-6.


Antitumor activity of genetically engineered NK-cells in non-hematological solid tumor: a comprehensive review.

Dash C, Sonowal D, Dhaka P, Yadav R, Chettri D, Satapathy B Front Immunol. 2024; 15:1390498.

PMID: 38694508 PMC: 11061440. DOI: 10.3389/fimmu.2024.1390498.


Association of preoperative and recurrent serum carcinoembryonic antigen and outcome of colorectal cancer patients with metastatic relapse.

Tong S, Wu R, Zhang L, Lu P, Hu X, Li Y Heliyon. 2024; 10(7):e29347.

PMID: 38617920 PMC: 11015133. DOI: 10.1016/j.heliyon.2024.e29347.


Anoikis-related genes as potential prognostic biomarkers in gastric cancer: A multilevel integrative analysis and predictive therapeutic value.

Lin Y, Liu J IET Syst Biol. 2024; 18(2):41-54.

PMID: 38377622 PMC: 10996445. DOI: 10.1049/syb2.12088.


Gold Nanotapes and Nanopinecones in a Quantitative Lateral Flow Assay for the Cancer Biomarker Carcinoembryonic Antigen.

Fox J, Batchelor D, Roberts H, Moorcroft S, Valleley E, Coletta P ACS Appl Nano Mater. 2023; 6(19):17769-17777.

PMID: 37854850 PMC: 10580237. DOI: 10.1021/acsanm.3c03053.


References
1.
Locker G, Hamilton S, Harris J, Jessup J, Kemeny N, Macdonald J . ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006; 24(33):5313-27. DOI: 10.1200/JCO.2006.08.2644. View

2.
Prete S, Turriziani M, Massara M, De Rossi A, Correale P, De Vecchis L . Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res. 2008; 27:5. PMC: 2438331. DOI: 10.1186/1756-9966-27-5. View

3.
Longley D, Johnston P . Molecular mechanisms of drug resistance. J Pathol. 2005; 205(2):275-92. DOI: 10.1002/path.1706. View

4.
Goldstein M, Mitchell E . Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest. 2005; 23(4):338-51. DOI: 10.1081/cnv-58878. View

5.
Ballesta A, Molina R, Filella X, Jo J, Gimenez N . Carcinoembryonic antigen in staging and follow-up of patients with solid tumors. Tumour Biol. 1995; 16(1):32-41. DOI: 10.1159/000217926. View